Bluebird Bio Inc (NASDAQ:BLUE) stock is enjoying a boost today, after an upgrade from Morgan Stanley to "equal-weight" from "underweight," with a price-target hike to $7.00 from $3.00. The firm anticipates BLUE to rise ahead of Dec. 20, the date the U.S. Food & Drug Administration (FDA) is expected to approve the company's sickle cell disease gene therapy, lovo-cel.
The stock was moving higher already, on track for its fourth-straight weekly win. It's also worth noting that though short interest has unwound, it still represents 20.7% of the stock's available float, or over six days' worth of pent-up buying power that could provide tailwinds.
Today, BLUE is surging out of penny stock territory for the first time since March, up 10.9% at $5.33 at last glance. The equity is also breaking above its 320-day moving average, which provided long-term pressure since January. Since the start of the year, Bluebird stock is still down 23.6%.
Call traders are eyeing the bull note with interest. So far, 5,938 calls have been exchanged -- eight times the call volume typically seen at this point -- in comparison to just 732 puts. The January 2025 10-strike call is the most popular, followed by the January 2024 5.50-strike call.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
